HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.

AbstractBACKGROUND AND PURPOSE:
Inflammation is considered to be involved in the pathogenesis of ischemic stroke. Our purpose was to assess the role of soluble intercellular adhesion molecule-1 (sICAM-1) concentration, a marker of inflammation, in predicting future ischemic stroke among patients at risk because of chronic coronary heart disease.
METHODS:
We obtained baseline serum samples from patients with chronic coronary heart disease enrolled in the Bezafibrate Infarction Prevention trial (n=3090), which assessed the efficacy of bezafibrate in secondary prevention. Using a prospective nested case-control design, we measured baseline sICAM-1 concentration in sera of patients who developed ischemic stroke during a mean follow-up of 8.2 years (cases, n=134) and in age- and sex-matched controls without any subsequent cardiovascular events (n=134).
RESULTS:
Baseline serum concentrations of sICAM-1 were significantly higher in cases compared with controls (379 versus 350 ng/mL, P<0.05). sICAM-1 concentration at the highest quartile (>394 ng/mL) was associated with significantly higher relative odds of ischemic stroke compared with the lower concentrations after adjustment for potential confounding variables (relative odds, 2.1; 95% CI, 1.1 to 4.3). After fibrinogen and total white blood cell count were added to the multivariable model, the relative odds were 2.1 (95% CI, 1.1 to 4.2) and 2.2 (95% CI, 1.1 to 4.8), respectively. The risk associated with raised concentrations of sICAM-1 seemed to be highest for large disabling strokes of cardioembolic origin.
CONCLUSIONS:
Elevated concentrations of sICAM-1, a marker of inflammation, are associated with increased risk of ischemic stroke, independent of other traditional cerebrovascular risk factors and of plasma fibrinogen, among patients at increased risk because of manifest coronary heart disease.
AuthorsDavid Tanne, Moti Haim, Valentina Boyko, Uri Goldbourt, Tamar Reshef, Shlomo Matetzky, Yehuda Adler, Yoseph A Mekori, Solomon Behar
JournalStroke (Stroke) Vol. 33 Issue 9 Pg. 2182-6 (Sep 2002) ISSN: 1524-4628 [Electronic] United States
PMID12215584 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • Hypolipidemic Agents
  • Intercellular Adhesion Molecule-1
  • Fibrinogen
  • Bezafibrate
Topics
  • Bezafibrate (therapeutic use)
  • Biomarkers (blood)
  • Brain Ischemia (blood, epidemiology)
  • Case-Control Studies
  • Chronic Disease
  • Cohort Studies
  • Comorbidity
  • Coronary Disease (blood, prevention & control)
  • Female
  • Fibrinogen (analysis)
  • Follow-Up Studies
  • Humans
  • Hypolipidemic Agents (therapeutic use)
  • Intercellular Adhesion Molecule-1 (blood)
  • Israel (epidemiology)
  • Logistic Models
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies
  • Randomized Controlled Trials as Topic (statistics & numerical data)
  • Risk
  • Risk Assessment
  • Risk Factors
  • Stroke (blood, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: